Asia
Novavax and Serum Institute of India Private Limited (SIIPL) amended an agreement struck last month that will allow the company to double the number of doses of its experimental COVID-19 vaccine for potential use in 2021.
The United Arab Emirates has granted Emergency Use Authorization to an investigational vaccine for the novel coronavirus six weeks after late-stage studies began.
Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
When biotech companies consider conducting business in China, their concerns are radically different than they were even four years ago.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
It was a busy week for clinical trial updates. Here’s a look.
The trial of Ninlaro drug for multiple myeloma did not meet statistical significance for the primary endpoint of progression-free survival (PFS).
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
PRESS RELEASES